Open AccessAntitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum‐Resistant Ovarian Cancer
Author(s) -
Inayama Yoshihide,
Hamanishi Junzo,
Matsumura Noriomi,
Murakami Ryusuke,
Abiko Kaoru,
Yamaguchi Ken,
Baba Tsukasa,
Horie Katsuyuki,
Konishi Ikuo,
Mandai Masaki
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2018-0167
Subject(s) - nivolumab , medicine , chemotherapy , oncology , ovarian cancer , refractory (planetary science) , nedaplatin , progressive disease , cancer , immunotherapy , cisplatin , physics , astrobiology
Platinum‐resistant recurrent ovarian cancer is generally refractory to chemotherapy. Programmed cell death‐1 (PD‐1) signaling is a new target for antitumor therapy. The anti‐PD‐1 antibody nivolumab had a 10% durable complete response rate in our phase II clinical trial. However, how nivolumab affects sensitivity to subsequent chemotherapy remains unclear. We encountered several cases of unexpected antitumor response among patients who underwent palliative chemotherapy in the follow‐up study of our phase II nivolumab trial (UMIN5714). Several agents had an unexpected antitumor response in patients who were resistant or refractory to standard chemotherapeutic agents. In one patient, both pegylated liposomal doxorubicin (PLD) and nedaplatin (CDGP) resulted in partial response. In another patient, PLD and CDGP resulted in partial response and stable disease, respectively. These two patients remained alive on the cutoff date. These two cases raise the possibility that nivolumab might improve sensitivity to adequate chemotherapy for ovarian cancer.